|This Slide: #26 of 100|
Slide #26. Eli Lilly and Company — Novartis Animal Health
Eli Lilly and Company (NYSE:LLY)
Novartis Animal Health
Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire Novartis Animal Health for approximately $5.4 billion in an all-cash transaction that will strengthen and diversify Lilly's own animal health business, Elanco. Upon completion of the acquisition, Elanco will be the second-largest animal health company in terms of global revenue, will solidify its number two ranking in the U.S., and improve its position in Europe and the rest of the world.
Eli Lilly and Company is engaged in discovering, developing, manufacturing, and marketing products in two business segments: human pharmaceutical products; and animal health products. Co.'s human pharmaceutical products include: cardiovascular, endocrinology, immunology, neuroscience and oncology products. Co.'s animal health products are comprised of products for animals, among others, which include Clynav, a vaccine to control pancreas disease in salmon; Coban®, Maxiban®, and Monteban®, anticoccidial agents for use in poultry; as well as products for companion animals, which include Comfortis®, a chewable tablet that kills fleas and prevents flea infestations on dogs.
Eli Lilly SEC Filing Email Alerts Service
Open the LLY Page at The Online Investor »
Buy (3.27 out of 4)
(ranked higher than approx. 52% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite